The New Magnificent Stocks to Own in 2026

Why It Matters

These companies signal a shift from mega‑cap tech dominance to diversified sectors, offering investors fresh growth engines amid rising infrastructure and health trends.

Key Takeaways

• MasTec's AI infrastructure exposure drives 225% share rise.
• Caterpillar benefits from booming construction, up 262% in five years.
• Walmart's e‑commerce shift fuels 164% stock gain.
• Eli Lilly's weight‑loss pipeline fuels 39.6% earnings jump.
• Howmet Aerospace's defense demand pushes 798% share surge.

Pulse Analysis

The end of the Magnificent 7 era has investors searching for the next set of market leaders. In the Zacks Market Edge podcast, Tracey Ryniec argues that the old tech‑centric narrative is giving way to sectors powered by infrastructure renewal, consumer fundamentals, and health innovation. This transition reflects broader macro trends: federal spending on roads and broadband, a post‑pandemic retail landscape, and a surge in demand for weight‑loss therapeutics and defense capabilities. Understanding these dynamics helps investors spot where capital is likely to flow in 2026.

MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace each exhibit distinct growth catalysts. MasTec’s role in building AI‑ready communications networks underpins its 225% five‑year rally, while Caterpillar benefits from a construction boom that has lifted its stock 262% and forecasts 18.9% earnings growth. Walmart’s hybrid brick‑and‑mortar‑online model drives a 164% share increase, and Eli Lilly’s pipeline of obesity drugs promises a 39.6% earnings jump. Howmet Aerospace, riding defense spending, has surged nearly 800%, albeit at a steep forward P/E of 56.

For portfolio construction, the new magnificent stocks offer diversification beyond the over‑valued mega‑cap tech space. Their premium multiples suggest confidence in sustained earnings expansion, but also imply higher valuation risk if growth stalls. Investors should weigh each company’s forward P/E against sector peers, monitor macro‑policy impacts on infrastructure and defense, and consider the timing of earnings catalysts such as drug approvals or equipment orders. Incorporating these picks can provide exposure to high‑growth themes while balancing the concentration risk that plagued the previous Magnificent 7 lineup.